Phio Pharmaceuticals Corp. announced on December 10, 2024, that it has been named a finalist for the Technology Disruptor of the Year Award. This award is part of Advanced Therapies Week 2025, a prominent cell and gene conference. The recognition celebrates exceptional contributions to the field of cell and gene therapy through technological innovation.
Phio's nomination specifically highlights its patented INTASYL technology, a unique siRNA platform capable of silencing any gene in the human genome. The company's lead INTASYL compound, PH-762, is currently completing a Phase 1b clinical study. Recent data from the second cohort of this study showed one patient with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance), and a second patient achieved a partial response (90% tumor clearance).
Robert Bitterman, CEO of Phio Pharmaceuticals, expressed pleasure at the mounting recognition for siRNA therapy and the INTASYL technology as a revolutionary treatment in oncological disease. This external validation underscores the innovative potential of Phio's technology in advancing cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.